Travere Therapeutics, Inc. (TVTX) Ownership
TVTX ownership summary
as of October 18, 2026- Institutions
- 116.0% of shares outstanding
- Insiders
- 0.69% of shares outstanding
- Shares outstanding
- 93.0M
- Float
- 93.2M shares available to trade
- Short interest
- 17.48% 12.7M shares short
- Days to cover
- 8.16 short interest down 2.3% vs prior month
- Institutions 116.02%
- Insiders 0.69%
TVTX top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | HHG PLC | 12.11% | 11.4M | $566.4M | +908,420 (+8.6%) | March 31, 2026 |
| 2 | Jupiter Topco LLC | 12.01% | 11.3M | $561.7M | +11.3M (0.0%) | June 30, 2026 |
| 3 | BlackRock Inc | 8.51% | 8.0M | $397.8M | +228,630 (+2.9%) | June 30, 2026 |
| 4 | FMR Inc | 7.53% | 7.1M | $352.0M | −3.9M (−35.3%) | June 30, 2026 |
| 5 | Bank of America Corp | 4.85% | 4.6M | $226.6M | +3.2M (+239.6%) | June 30, 2026 |
| 6 | State Street Corp | 4.52% | 4.3M | $211.1M | −703,764 (−14.2%) | June 30, 2026 |
| 7 | Vanguard Capital Management, LLC | 4.36% | 4.1M | $203.8M | +62,882 (+1.6%) | June 30, 2026 |
| 8 | Perceptive Advisors LLC | 3.98% | 3.8M | $186.1M | −389,977 (−9.4%) | June 30, 2026 |
| 9 | Delaware Management Holdings Inc | 2.98% | 2.8M | $139.5M | −457,999 (−14.0%) | June 30, 2026 |
| 10 | Adage Capital Partners Gp LLC | 2.73% | 2.6M | $127.4M | +1.6M (+163.0%) | June 30, 2026 |
| 11 | Geode Capital Management, LLC | 2.52% | 2.4M | $117.6M | +2,328 (+0.1%) | June 30, 2026 |
| 12 | Rock Springs Capital Management LP | 2.31% | 2.2M | $108.1M | +701,115 (+47.4%) | June 30, 2026 |
| 13 | Kynam Capital Management, LP | 2.12% | 2.0M | $99.2M | +430,982 (+27.5%) | June 30, 2026 |
| 14 | Stephens Inv Mgmt Group LLC | 1.99% | 1.9M | $93.0M | +76,838 (+4.3%) | June 30, 2026 |
| 15 | Renaissance Technologies Corp | 1.94% | 1.8M | $90.9M | −133,700 (−6.8%) | June 30, 2026 |
| 16 | Emerald Advisers, LLC | 1.70% | 1.6M | $79.4M | +43,690 (+2.8%) | June 30, 2026 |
| 17 | Armistice Capital, LLC | 1.67% | 1.6M | $78.0M | −3.3M (−67.9%) | June 30, 2026 |
| 18 | Two Sigma Investments LLC | 1.66% | 1.6M | $77.7M | +57,397 (+3.8%) | June 30, 2026 |
| 19 | Vanguard Portfolio Management, LLC | 1.64% | 1.5M | $76.5M | −167,522 (−9.8%) | June 30, 2026 |
| 20 | The Goldman Sachs Group Inc | 1.63% | 1.5M | $76.2M | −184,400 (−10.7%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 12 holders added 18.7M shares and 8 cut 9.2M.
TVTX top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 3.13% | 3.0M | $146.5M | −3,717 (−0.1%) | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 2.45% | 2.3M | $114.6M | −26,624 (−1.1%) | September 30, 2026 |
| 3 | State Street® SPDR® S&P® Biotech ETF | 2.38% | 2.2M | $111.4M | −42,750 (−1.9%) | September 30, 2026 |
| 4 | Nomura Small Cap Core I | 1.66% | 1.6M | $77.8M | −214,252 (−12.0%) | August 31, 2026 |
| 5 | Janus Henderson Global Life Sciences D | 1.47% | 1.4M | $68.8M | −50,693 (−3.5%) | August 31, 2026 |
| 6 | Vanguard Explorer Inv | 1.44% | 1.4M | $67.4M | +101,399 (+8.1%) | June 30, 2026 |
| 7 | Janus Global Life Science AUSD | 1.41% | 1.3M | $66.1M | +6,772 (+0.5%) | June 30, 2026 |
| 8 | Janus Henderson Glb Life Scn I2 USD | 1.41% | 1.3M | $65.9M | −3,186 (−0.2%) | August 31, 2026 |
| 9 | Janus Henderson Hrzn Biotec E2 USD | 1.37% | 1.3M | $63.9M | +25,699 (+2.0%) | June 30, 2026 |
| 10 | Janus Henderson Triton D | 1.19% | 1.1M | $55.5M | — | August 31, 2026 |
| 11 | Vanguard Small Cap Index | 1.12% | 1.1M | $52.6M | +1.1M (0.0%) | September 30, 2026 |
| 12 | Fidelity Small Cap Index | 1.04% | 977K | $48.5M | +8,306 (+0.9%) | July 31, 2026 |
| 13 | iShares Russell 2000 Growth ETF | 0.89% | 836K | $41.5M | −1,058 (−0.1%) | September 30, 2026 |
| 14 | Fidelity Select Biotechnology | 0.85% | 799K | $39.6M | — | August 31, 2026 |
| 15 | Fidelity Blue Chip Growth | 0.80% | 750K | $37.2M | −163,900 (−17.9%) | August 31, 2026 |
| 16 | Fidelity Small Cap Growth | 0.79% | 743K | $36.9M | — | July 31, 2026 |
| 17 | iShares Biotechnology ETF | 0.76% | 713K | $35.4M | −5,400 (−0.8%) | September 30, 2026 |
| 18 | Xtrackers MSCI World Swap ETF 1C | 0.75% | 710K | $35.2M | −4,473 (−0.6%) | December 31, 2025 |
| 19 | MEDICAL BioHealth EUR Acc | 0.71% | 668K | $33.1M | +141 (+0.0%) | August 31, 2026 |
| 20 | HBM Healthcare Investments AG Ord | 0.69% | 652K | $32.4M | +215,000 (+49.2%) | June 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
TVTX insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-22 | William E Rote | Sell | $39.09 | 9,100 | $355,719 |
| 2026-04-15 | Christopher R Cline | Sell | $42.61 | 1,014 | $43,207 |
| 2026-04-15 | Elizabeth E Reed | Sell | $41.83 | 6,785 | $283,817 |
| 2026-04-15 | Eric M Dube | Sell | $41.09 | 64,000 | $2.6M |
| 2026-04-15 | Jula Inrig | Sell | $42.61 | 1,018 | $43,377 |
| 2026-04-14 | Elizabeth E Reed | Sell | $41.21 | 44,715 | $1.8M |
| 2026-04-14 | Jula Inrig | Sell | $41.93 | 7,215 | $302,525 |
| 2026-04-14 | Christopher R Cline | Sell | $41.93 | 7,248 | $303,909 |
| 2026-04-14 | Sandra Calvin | Sell | $41.07 | 21,977 | $902,595 |
| 2026-04-14 | Gary A Lyons | Sell | $41.07 | 8,000 | $328,560 |
| 2026-04-14 | Peter Heerma | Sell | $41.93 | 7,215 | $302,525 |
| 2026-04-14 | Roy D Baynes | Sell | $41.29 | 32,750 | $1.4M |
| 2026-04-13 | Christopher R Cline | Sell | $28.85 | 65 | $1,875 |
| 2026-04-06 | Roy D Baynes | Sell | $33.00 | 10,000 | $330,000 |
| 2026-04-01 | Eric M Dube | Sell | $30.93 | 60,000 | $1.9M |
| 2026-04-01 | Elizabeth E Reed | Sell | $30.00 | 10,000 | $300,000 |
| 2026-03-16 | Elizabeth E Reed | Sell | $28.09 | 10,000 | $280,900 |
| 2026-02-04 | Jula Inrig | Sell | $32.21 | 1,779 | $57,302 |
| 2026-02-04 | Christopher R Cline | Sell | $32.19 | 1,745 | $56,172 |
| 2026-02-04 | Elizabeth E Reed | Sell | $32.18 | 2,994 | $96,347 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
TVTX shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns TVTX
Institutional investors own 116.0% of Travere Therapeutics's shares and insiders 0.69%. The largest holder is HHG PLC with 12.11% of the shares (11.4M), as of March 31, 2026. Among the top 20 institutions, 12 added shares and 8 reduced their stake in the latest filings. Short interest is 17.48% of the float, or 8.16 days of average trading volume. The share count rose 197.2% since 2014.
Related: TVTX analyst forecast, TVTX key metrics. See the TVTX stock overview for the latest quote and news.
TVTX ownership FAQ
Who owns the most Travere Therapeutics stock?
The largest shareholders of Travere Therapeutics are HHG PLC (12.11%), Jupiter Topco LLC (12.01%), BlackRock Inc (8.51%), FMR Inc (7.53%), Bank of America Corp (4.85%).
What percentage of Travere Therapeutics is owned by institutions?
Institutions hold 116.0% of Travere Therapeutics's shares outstanding; insiders hold 0.69%.
Which funds own Travere Therapeutics?
The largest fund holders of Travere Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (3.13%), iShares Russell 2000 ETF (2.45%), State Street® SPDR® S&P® Biotech ETF (2.38%), Nomura Small Cap Core I (1.66%), Janus Henderson Global Life Sciences D (1.47%).
What is Travere Therapeutics's short interest?
12.7M shares of Travere Therapeutics were sold short, 17.48% of the float; at the average daily volume it would take 8.16 days to cover.
Are insiders buying or selling Travere Therapeutics?
Of the latest 20 reported insider transactions in Travere Therapeutics (since February 4, 2026), 0 were purchases and 20 were sales.
How many shares of Travere Therapeutics are outstanding?
Travere Therapeutics has 93.0M shares outstanding, of which 93.2M are in the public float.